Company / Current Liabilities
Matinas BioPharma Holdings, Inc. Current Liabilities History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$2.7M
FY2024
5-year range
$2.6M / $4.3M
FY2020-FY2024
Trend
+1.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities returned to growth in FY2024 after 2 years of decline, reaching $3M.
Based on SEC 10-K filings.
$3M in FY2024 with a 5-year CAGR of -3.0%.
Improved from $4M to $3M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -15.0%
- 5-Year CAGR
- -3.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.0%, indicating a declining trend.
- In FY2024, current liabilities increased 1.7% year-over-year.
- Peak current liabilities was recorded in FY2021.
- Lowest current liabilities in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.7M | +1.7% |
| FY2023 | $2.6M | -38.8% |
| FY2022 | $4.3M | -1.4% |
| FY2021 | $4.3M | +21.9% |
| FY2020 | $3.6M | +15.2% |
| FY2019 | $3.1M | +9.1% |
| FY2018 | $2.8M | +27.7% |
| FY2017 | $2.2M | +54.0% |
| FY2016 | $1.4M | +28.0% |
| FY2015 | $1.1M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026